Honz Pharmaceutical Co., Ltd.

Equities

300086

CNE100000QM6

Pharmaceuticals

End-of-day quote Shenzhen S.E. 06:00:00 2024-04-25 pm EDT 5-day change 1st Jan Change
4.68 CNY +1.08% Intraday chart for Honz Pharmaceutical Co., Ltd. +6.36% -20.27%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Hainan Yougeng Investment Co., Ltd. agreed to acquire Guangdong Yuanning Pharmaceutical Co.,Ltd. from Honz Pharmaceutical Co., Ltd. for CNY12 million. CI
Honz Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Honz Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Honz Pharmaceutical Co., Ltd. cancelled the transaction announced on June 30, 2022 CI
Honz Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Honz Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Honz Pharma Optimistic Shortage of Fever Medicine Will be Solved MT
Honz Pharmaceutical Co., Ltd. Announces Directorate Appointments CI
Honz Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Honz Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Honz Pharmaceutical Co., Ltd. announced that it expects to receive CNY 297.2405 million in funding CI
Honz Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Honz Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Beijing Adds Fertility Treatment in Medical Insurance Program; Fertility Pharma Stocks Jump MT
Honz Pharmaceutical Co., Ltd. cancelled the transaction announced on November 9, 2020 CI
Honz Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021 CI
Honz Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021 CI
Honz Pharmaceutical Co., Ltd. Announces Implementation of 2020 Final Profit Distribution Plan, Payable on August 13, 2021 CI
Honz Pharmaceutical Co., Ltd. Approves 2020 Profit Distribution Plan At the Annual General Meeting Held on June 29, 2021 CI
Jinxin Fertility : to Buy 10% Stake in Controlling Shareholder of Two Hospitals for $6 Million MT
Honz Pharmaceutical Co., Ltd. Announces Earnings Results for the First Quarter Ended March 31, 2021 CI
Honz Pharmaceutical Co., Ltd. Announces Final Profit Distribution Proposal for 2020 CI
Honz Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2020 CI
Honz Pharmaceutical Co., Ltd. announced that it expects to receive CNY 634.6114 million in funding CI
Honz Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2020 CI
Chart Honz Pharmaceutical Co., Ltd.
More charts
HONZ PHARMACEUTICAL CO., LTD., formerly HAINAN HONZ PHARMACEUTICAL CO., LTD., is principally engaged in the research, development, production and distribution of drugs for children. The Company provides western medicines and Chinese patent drugs, including antipyretic and analgesic drugs, cold drugs, antibiotics drugs, respiratory system drugs, digestant and arresting convulsion drugs, as well as nutrition drugs, among others. The Company's products include nimesulide granules, cefminox sodium for injection, Zhike Juhong granules, Ganmao Qingre granules, artificial cow-bezoar and chlorphenamine maleate granules, cefaclor granules, carbocisteine granules, Jianerle granules, pediatric four vitaminsand calcium gluconate granules, as well as ribavirin pellets and Norfloxacin capsules for adults.
Calendar
More about the company
  1. Stock Market
  2. Equities
  3. 300086 Stock
  4. News Honz Pharmaceutical Co., Ltd.
  5. Honz Pharma Optimistic Shortage of Fever Medicine Will be Solved